Department of Pharmacology, Faculty of Medicine, University of Latvia, 3 Jelgavas St, Riga, 1004, Latvia.
Department of Stem Cell Biology, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
Cell Mol Neurobiol. 2021 Apr;41(3):605-613. doi: 10.1007/s10571-020-00865-8. Epub 2020 May 14.
We have recently demonstrated that extracellular vesicles (EVs) derived from the human teeth stem cells improve motor symptoms and normalize tyrosine hydroxylase (TH) expression in the nigrostriatal structures of Parkinson's disease (PD) model rats obtained by 6-hydroxydopamine (6-OHDA) unilateral injection into the medial forebrain bundle (MFB). The aim of this study was to clarify: (1) how long therapeutic effects persist after discontinuation of 17-day intranasal administration of EVs in 6-OHDA rats; (2) may EVs reverse cognitive (learning/memory) dysfunction in these PD model rats; (3) whether and how the behavioral improvement may be related to the expression of TH and Nissl bodies count in the nigrostriatal structures. Our results demonstrated that in 6-OHDA rats, gait was normalized even ten days after discontinuation of EVs administration. EVs successfully reversed 6-OHDA-induced impairment in spatial learning/memory performance; however, the beneficial effect was shorter (up to post-treatment day 6) than that revealed for gait improvement. The shorter effect of EVs coincided with both full normalization of TH expression and Nissl bodies count in the nigrostriatal structures, while slight but significant increase in the 6-OHDA-decreased Nissl count persisted in the substantia nigra even on the post-treatment day 20, supposedly due to the continuation of protein synthesis in the living cells. The obtained data indicate the usefulness of further studies to find the optimal administration regimen which could be translated into clinical trials on PD patients, as well as to clarify other-apart from dopaminergic-neuromodulatory pathways involved in the EVs mechanism of action.
我们最近证明,来源于人牙髓干细胞的细胞外囊泡(EVs)通过单侧内侧前脑束(MFB)注射 6-羟多巴胺(6-OHDA)到帕金森病(PD)模型大鼠中,改善了运动症状并使黑质纹状体结构中的酪氨酸羟化酶(TH)表达正常化。本研究的目的是阐明:(1)停止用 EV 鼻内给药 17 天后,治疗效果能持续多久;(2)EV 是否可以逆转这些 PD 模型大鼠的认知(学习/记忆)功能障碍;(3)行为改善是否以及如何与黑质纹状体结构中 TH 和尼氏小体计数的表达相关。我们的结果表明,在 6-OHDA 大鼠中,即使在停止 EV 给药十天后,步态也恢复正常。EV 成功地逆转了 6-OHDA 引起的空间学习/记忆功能障碍;然而,其有益作用(最多持续到治疗后第 6 天)比步态改善的作用短。EV 较短的作用与 TH 表达和黑质纹状体结构中的尼氏小体计数完全正常化一致,而在治疗后第 20 天,黑质中 6-OHDA 减少的尼氏小体计数仍然略有但显著增加,这可能是由于活细胞中蛋白质合成的继续。获得的数据表明,有必要进一步研究以找到最佳给药方案,这可能转化为 PD 患者的临床试验,并阐明除了涉及 EV 作用机制的多巴胺能神经调节途径之外的其他途径。